Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial Academic Article uri icon

Overview

MeSH Major

  • Antihypertensive Agents
  • Epoprostenol
  • Hypertension, Pulmonary
  • Scleroderma, Systemic

abstract

  • Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease.

authors

publication date

  • March 21, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10733441

Additional Document Info

start page

  • 425

end page

  • 34

volume

  • 132

number

  • 6